138 related articles for article (PubMed ID: 16622871)
1. Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic.
Barin F; Plantier JC; Brand D; Brunet S; Moreau A; Liandier B; Thierry D; Cazein F; Lot F; Semaille C; Desenclos JC
J Med Virol; 2006; 78 Suppl 1():S13-8. PubMed ID: 16622871
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots.
Barin F; Meyer L; Lancar R; Deveau C; Gharib M; Laporte A; Desenclos JC; Costagliola D
J Clin Microbiol; 2005 Sep; 43(9):4441-7. PubMed ID: 16145089
[TBL] [Abstract][Full Text] [Related]
3. Preliminary results from the new HIV surveillance system in France.
Lot F; Semaille C; Cazein F; Barin F; Pinget R; Pillonel J; Desenclos JC
Euro Surveill; 2004 Oct; 9(10):34-7. PubMed ID: 15507728
[TBL] [Abstract][Full Text] [Related]
4. Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays.
Zouhair S; Roussin-Bretagne S; Moreau A; Brunet S; Laperche S; Maniez M; Barin F; Harzic M
J Clin Microbiol; 2006 Feb; 44(2):662-5. PubMed ID: 16455942
[TBL] [Abstract][Full Text] [Related]
5. Serotyping and genotyping of HIV-1 infection in residents of Khayelitsha, Cape Town, South Africa.
Jacobs GB; de Beer C; Fincham JE; Adams V; Dhansay MA; van Rensburg EJ; Engelbrecht S
J Med Virol; 2006 Dec; 78(12):1529-36. PubMed ID: 17063507
[TBL] [Abstract][Full Text] [Related]
6. Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France.
Semaille C; Barin F; Cazein F; Pillonel J; Lot F; Brand D; Plantier JC; Bernillon P; Le Vu S; Pinget R; Desenclos JC
J Infect Dis; 2007 Aug; 196(3):377-83. PubMed ID: 17597452
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States.
Sullivan PS; Do AN; Ellenberger D; Pau CP; Paul S; Robbins K; Kalish M; Storck C; Schable CA; Wise H; Tetteh C; Jones JL; McFarland J; Yang C; Lal RB; Ward JW
J Infect Dis; 2000 Feb; 181(2):463-9. PubMed ID: 10669327
[TBL] [Abstract][Full Text] [Related]
8. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype.
Walker PR; Cilliers T; Choge IA; Taylor N; Cohen SS; Morris L
J Med Virol; 2006 Oct; 78(10):1262-8. PubMed ID: 16927278
[TBL] [Abstract][Full Text] [Related]
9. Genetic variability of principal neutralizing determinants on HIV-1 gp41 and its correlation with subtypes.
Dong XN; Ying J; Wu Y; Chen YH
Immunol Lett; 2005 Oct; 101(1):104-7. PubMed ID: 15961163
[TBL] [Abstract][Full Text] [Related]
10. HIV global surveillance: foundation for retroviral discovery and assay development.
Brennan CA; Bodelle P; Coffey R; Harris B; Holzmayer V; Luk KC; Swanson P; Yamaguchi J; Vallari A; Devare SG; Schochetman G; Hackett J
J Med Virol; 2006; 78 Suppl 1():S24-9. PubMed ID: 16622874
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the dried blood spot filter paper technology and five testing strategies of HIV-1 and HIV-2 infections in West Africa.
Sarge-Njie R; Schim Van Der Loeff M; Ceesay S; Cubitt D; Sabally S; Corrah T; Whittle H
Scand J Infect Dis; 2006; 38(11-12):1050-6. PubMed ID: 17148076
[TBL] [Abstract][Full Text] [Related]
12. [Serotypes of the human immunodeficiency virus type 1 in Madrid].
Soriano V; Dietrich U; Mas A; Andersen R; Bravo R; Ruppach H; Gutiérrez M; Martínez-Zapico R; Rübsamen-Waigmann H; González-Lahoz J
Med Clin (Barc); 1997 Feb; 108(6):217-20. PubMed ID: 9102487
[TBL] [Abstract][Full Text] [Related]
13. Chimeric multiple antigenic peptides for simultaneous detection of specific antibodies to HIV-1 groups M, N, O, and HIV-2.
Pau CP; Luo W; McDougal JS
J Immunol Methods; 2007 Jan; 318(1-2):59-64. PubMed ID: 17169369
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic challenges for rapid human immunodeficiency virus assays. Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples.
Constantine NT; Zekeng L; Sangare AK; Gurtler L; Saville R; Anhary H; Wild C
J Hum Virol; 1997; 1(1):45-51. PubMed ID: 10195230
[TBL] [Abstract][Full Text] [Related]
15. Collection of phage-peptide probes for HIV-1 immunodominant loop-epitope.
Palacios-Rodríguez Y; Gazarian T; Rowley M; Majluf-Cruz A; Gazarian K
J Microbiol Methods; 2007 Feb; 68(2):225-35. PubMed ID: 17046088
[TBL] [Abstract][Full Text] [Related]
16. Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection.
Mauclère P; Damond F; Apetrei C; Loussert-Ajaka I; Souquière S; Buzelay L; Dalbon P; Jolivet M; Mony Lobe M; Brun-Vézinet F; Simon F; Barin F
AIDS Res Hum Retroviruses; 1997 Aug; 13(12):987-93. PubMed ID: 9264285
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of HIV-2 and HIV-1 group O infections among new HIV diagnoses in France: 2003-2006.
Barin F; Cazein F; Lot F; Pillonel J; Brunet S; Thierry D; Damond F; Brun-Vézinet F; Desenclos JC; Semaille C
AIDS; 2007 Nov; 21(17):2351-3. PubMed ID: 18090288
[TBL] [Abstract][Full Text] [Related]
18. [Report of the first 2 cases of HIV-1 group O infection in Spain].
García-Lerma G; Gutiérrez M; Mas A; Bravo R; Aguilera O; Soriano V
Med Clin (Barc); 1996 Oct; 107(11):418-21. PubMed ID: 9045005
[TBL] [Abstract][Full Text] [Related]
19. [Variability of human immunodeficiency virus type 1].
Brun-Vézinet F; Damond F; Simon F
Bull Soc Pathol Exot; 1999; 92(4):261-3. PubMed ID: 10572662
[TBL] [Abstract][Full Text] [Related]
20. Sequence of gp41env immunodominant region of HIV type 1 group O from west central Africa.
Brennan CA; Hackett J; Zekeng L; Lund JK; Vallari AS; Hickman RK; Gürtler L; Kaptue L; Von Overbeck J; Hampl H; Devare SG
AIDS Res Hum Retroviruses; 1997 Jul; 13(10):901-4. PubMed ID: 9197385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
